Upinitatug rilsodotin

DB19104InvestigationalProtein Based Therapies

Upinitatug rilsodotin is under investigation in clinical trial NCT05329545 (Upifitamab Rilsodotin Maintenance in Platinum-sensitive Recurrent Ovarian Cancer (UP-NEXT)).

Mechanism: Pharmacologically active on Sodium-dependent phosphate transport protein 2B
Curator reviewed
Also known as: Anti-napi2b/auristatin f-hpa adc xmt-1536 · Antibody-drug conjugate adc xmt-1536
Code names: ANTI-NAPI2B ADC XMT-1536 · XMT-1536

Resolves to

Compound

UNIIE8US1SQ3B5CAS2254119-00-9

Targets

O95436SLC34A2

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Upinitatug rilsodotin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account